Last reviewed · How we verify
Corectim (DELGOCITINIB)
Delgocitinib works by blocking the JAK2 enzyme, which plays a key role in the immune system's inflammatory response.
At a glance
| Generic name | DELGOCITINIB |
|---|---|
| Sponsor | Japan Tobacco |
| Drug class | Janus Kinase Inhibitor [EPC] |
| Target | Tyrosine-protein kinase JAK2 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Think of the immune system like a fire alarm. When the alarm is triggered, it sends out signals to fight off the perceived threat. Delgocitinib helps to turn down the volume on the alarm, reducing the inflammation and itching associated with atopic dermatitis.
Approved indications
- Atopic dermatitis
Common side effects
- Application site pain
- Paresthesia
- Pruritus
- Erythema
- Bacterial skin infections
- Finger cellulitis
- Paronychia
- Other skin infections
- Leukopenia
- Neutropenia
Serious adverse events
- Eczema herpeticum
- Herpes zoster
Key clinical trials
- Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris (PHASE2)
- A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis (PHASE2)
- A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus (PHASE3)
- The Role of Janus Kinase (JAK) and Voltage-gated Sodium Channels (Nav) on Pain and Itch (NA)
- A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema (PHASE3)
- Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema (PHASE3)
- A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema (PHASE3)
- Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Corectim CI brief — competitive landscape report
- Corectim updates RSS · CI watch RSS
- Japan Tobacco portfolio CI